Details for New Drug Application (NDA): 021269

✉ Email this page to a colleague

NDA 021269 describes CARDURA XL, which is a drug marketed by Viatris and is included in one NDA. It is available from one supplier. Additional details are available on the CARDURA XL profile page.

The generic ingredient in CARDURA XL is doxazosin mesylate. There are fourteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.

Summary for 021269

Tradename:	CARDURA XL
Applicant:	Viatris
Ingredient:	doxazosin mesylate
Patents:	0

Pharmacology for NDA: 021269

Mechanism of Action	Adrenergic alpha-Antagonists

Medical Subject Heading (MeSH) Categories for 021269

Adrenergic alpha-1 Receptor Antagonists
Antihypertensive Agents

Suppliers and Packaging for NDA: 021269

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
CARDURA XL	doxazosin mesylate	TABLET, EXTENDED RELEASE;ORAL	021269	NDA	Viatris Specialty LLC	58151-078	58151-078-93	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (58151-078-93)
CARDURA XL	doxazosin mesylate	TABLET, EXTENDED RELEASE;ORAL	021269	NDA	Viatris Specialty LLC	58151-079	58151-079-93	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (58151-079-93)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	EQ 4MG BASE
Approval Date:	Feb 22, 2005	TE:		RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	EQ 8MG BASE
Approval Date:	Feb 22, 2005	TE:		RLD:	Yes

Expired US Patents for NDA 021269

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	CARDURA XL	doxazosin mesylate	TABLET, EXTENDED RELEASE;ORAL	021269-002	Feb 22, 2005	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.